The Latest Breaking News from ABT

The iconic British brand announced in March that it would return to motorsport for the first time in more than a decade as a powertrain supplier in the all-electric championship, starting with the 2024-25 season.

Abbott has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.

The long-expected confirmation comes only weeks after it was revealed ahead of the Tokyo E-Prix that Lola Cars would be returning to motorsport after more than a decade away, while Yamaha would be venturing into four-wheel racing again for the first time since 1997.

Motorsport fans of a certain age will need no reminder about how both Lola and Yamaha endured generally torrid Formula 1 campaigns 27 years ago, the last for each in the category. The former botched its attempt to make the grade after both of its drivers comprehensively failed to qualify…

Abbott Laboratories' Q4 earnings report and stock performance analysis, highlighting limited growth potential.

Abbott's earnings guidance slightly missed expectations at the midpoint Wednesday, and ABT stock fell within a saucer base.

The medical sector is poised for substantial gains this year, fueled by rising cases of chronic diseases and swift technological progress. In light of this, let’s analyze the fundamentals of three medical stocks: Abbott Laboratories (ABT), Agilent Technologies (A), and Viemed Healthcare (VMD). Read on….

During the Mexico City E-Prix race meeting, it was revealed that Abt had terminated its contract with Mahindra on the eve of the season-opener, with the collaboration set to finish at the end of 2024.

During the Mexico City E-Prix race meeting it was revealed that Abt had terminated its contract with Mahindra on the eve of the season-opener, with the collaboration set to finish at the end of 2024.